PDCD1 and ovarian carcinoma: The efficacy of combining HDACi with PD-1 inhibitors has been evaluated in multiple preclinical cancer models, including melanoma, ovarian cancer, breast cancer, and lung cancer, showing great promise (136, 182, 183).